SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires latest quarterly results are driving discussion, with weaker operating performance in insurance, particularly GEICO, contrasted with a sharp increase in share repurchases. Traders are split between viewing the buybacks and large cash reserve as signs of management confidence and questioning whether the earnings softness and limited capital deployment will weigh on the shares.

Select Sector SPDR Trust (The) - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

XLF is drawing attention after a sharp reversal from recent highs, with put-heavy options activity fueling debate over whether traders are hedging or positioning for further weakness. Bearish concerns center on credit risks, higher rates and banks exposure to AI-related debt, while some see the decline as ordinary profit-taking rather than a broader breakdown.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Traders are debating whether Accenture can turn AI consulting projects into funded client deployments, with concerns that budget scrutiny and automation could squeeze billable hours and margins. Bearish commentary also points to resistance near $260 and an elevated RSI, while some investors remain positive on the companys recent run and insider buying.

NextEra Energy, Inc. engages in the provision of renewable energy. It operates through the Florida Power and Light Company (FPL) and NextEra Energy Resources and NEET (NEER). The FPL segment involves the generation, transmission, distribution, and sale of electric energy in Florida. The NEER segment produces electricity from clean and renewable sources, including wind and solar. The company was founded on December 28, 1925 and is headquartered in Juno Beach, FL.

NextEra Energy Inc

NextEras exposure to rising AI data-center electricity demand is drawing attention, alongside debate over the grid investment needed to serve it. Bulls see a power-demand growth opportunity, while skeptics note that project queues are not firm revenue and warn that unapproved buildout costs could fall on shareholders or ratepayers.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines initial RASONQUE launch and quarterly results are driving attention, with traders highlighting stronger-than-expected early demand while debating whether high spending and the durability of the sales ramp justify the valuation. The discussion also points to a pending European decision and first-line pancreatic-cancer trials as potential next milestones.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Attention centers on lorundrostats upcoming AHA data and FDA review, with traders also discussing reports that blood-pressure benefits persisted after treatment ended. The community is split between optimism about the clinical profile and concern that Mineralys may struggle to commercialize against AstraZeneca, as the shares remain under pressure.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,366,684,616.305855 in circulation. The last known price of Stellar is 0.15346137 USD and is down -1.11 over the last 24 hours. It is currently trading on 848 active market(s) with $109,670,947.94 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention for its persistent price weakness and repeated selloffs, with traders debating whether broader crypto-market pressure or ongoing selling is responsible. Optimists cite Stellars institutional tokenization developments, including DTCC plans, while skeptics argue that adoption has not translated into token demand or price gains.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention amid a technology-sector correction and concerns that concentrated AI and data-center spending may not generate adequate returns. Traders point to mostly put-heavy options activity, debating whether it reflects hedging or bearish bets, while some see the pullback as an opportunity to buy.

NRG Energy, Inc. engages in the production, sale, and distribution of energy and energy services. It operates through the following segments: Texas, East, West/Services/Other, Vivint Smart Home, and Corporate Activities. The Texas segment includes all activities related to customer, plant and market operations in Texas, other than Cottonwood. The East segment engages in all activities related to customer, plant and market operations in the East. The West/Services/Other segment is focused on all activities related to customer, plant and market operations in the West and Canada, and activities related to the Cottonwood facility and other investments. The Vivint Smart Home segment is a smart home platform that provides customers with technology, products and services to create a smarter, greener, safer home. The company was founded in 1989 and is headquartered in Houston, TX.

NRG Energy Inc.

NRG is drawing attention after a sharp, volatile rebound following a prolonged selloff, with traders debating whether AI-driven electricity demand can support its growth story or whether uncertain data-center demand and power prices pose risks. Some also point to unusual options and off-exchange trading, while others are watching for the next earnings report.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,078,194,480.417637 in circulation. The last known price of Algorand is 0.09693394 USD and is up 3.39 over the last 24 hours. It is currently trading on 586 active market(s) with $57,858,585.39 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

ALGO is drawing attention amid weak, volatile price action around the 910-cent area, with traders debating whether it can hold support and break resistance or continue lower. Bulls point to a possible altcoin rebound and Algorands quantum-resistant and tokenization features, while bears cite its prolonged underperformance and see further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evogene Schedules Third Quarter 2026 Financial Results Release

Evogene Schedules Third Quarter 2026 Financial Results Release Evogene Schedules Third Quarter 2026 Financial Results ReleasePR NewswireREHOVOT, Israel, Nov. 5, 2026 Zoom conference call scheduled for November 19, 2026, 9:00 AM ETREHOVOT, Israel, Nov. 5, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq...

Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery ProgramPR NewswireREHOVOT, Israel, Oct...

Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain

Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in SpainPR NewswireREHOVOT, Israel, Oct. 26, 2026 Company to Attend BIO-Europe in Cologne, Germany, and...

Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL

Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeILPR NewswireREHOVOT, Israel, Oct. 20, 2026 The roadshow...

Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors

Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of DirectorsPR NewswireREHOVOT, Israel, Oct. 6, 2026REHOVOT, Israel, Oct. 6...

Evogene Gets 180-day Nasdaq Extension To Regain Compliance

(RTTNews) - Israeli computational chemistry company Evogene Ltd. (EVGN), announced on Wednesday that it has received an additional 180 days from Nasdaq to regain compliance with the minimum $1 bid price requirement...

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price CompliancePR NewswireREHOVOT, Israel, Sept. 30, 2026REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- Evogene Ltd...

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market session. The company's market cap stands at $4.5 million.
AIxCrypto Hldgs (NASDAQ:AIXC) stock moved upwards byread more...

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward PR Newswire REHOVOT, Israel, Aug. 31, 2026 Company urges shareholders to...

Evogene (EVGN) Q2 2026 Earnings Call Transcript

Evogene (EVGN) Q2 2026 Earnings Call Transcript...

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

Evogene Ltd

Why Did EVGN Shares Drop More Than 14% Today?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The proceeds are intended to be used for working capital and other general corporate purposes.</li><li>The computational chemistry company expects the transaction to close on or about Wednesday.&nbsp;</li><li>Earlier on Tuesday, the company announced an expanded collaboration with Google Cloud to integrate advanced AI agents into its ChemPass AI platform using Vertex AI.</li></ul>Shares of Evogene Ltd. (EVGN) fell more than 14% on Tuesday after the company announced that it had entered into a warrant inducement agreement with an existing institutional investor.The existing warrants would be exercised at a reduced price of $1.00 for total gross cash proceeds of approximately $3.4 million, before deducting financial advisor fees and other transaction expenses, the company said.The proceeds are intended to be used for working capital and other general corporate purposes.The computational chemistry company expects the transaction to close on or about Wednesday.<h2 class="st-heading-2">Deal Details</h2>Evogene said the transaction would include the immediate exercise of August 2024 Series A ordinary warrants to purchase up to 1,692,308 ordinary shares and August 2024 Series B ordinary warrants to purchase up to 1,692,308 ordinary shares.In return for these existing warrants being exercised, the investor will receive new unregistered warrants in a private placement, the company said. These new warrants will allow the purchase of up to 5,076,924 additional ordinary shares at an exercise price of $1.25 per share.The new Series A-1 warrants and the Series B-1 warrants will expire in five years and 18 months respectively. Both will be immediately exercisable upon issuance.<h2 class="st-heading-2">About Evogene</h2>Evogene is an Israel-based micro-cap computational chemistry company that specializes in the use of artificial intelligence (AI) for the discovery and development of life-science-based products.The company uses its proprietary ChemPass AI platform to generatively design novel, high-potency small molecules for pharma and agriculture.Earlier on Tuesday, the company announced an expanded collaboration with Google Cloud to integrate advanced AI agents into its ChemPass AI platform using Vertex AI.The deal aims to automate workflows, accelerate small-molecule discovery, improve accuracy and efficiency, and build on a prior generative AI model partnership to strengthen Evogene’s pharma and agriculture innovation pipeline.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/EVGN">EVGN shares</a> was in the ‘extremely bullish’ territory at the time of writing amid ‘extremely high’ message volumes.Shares of EVGN have declined more than 33% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/oracle-stock-rises-more-than-4.5-percent-to-one-week-high/cZbUghtR4pX">Oracle Stock Rises More Than 4.5% To One-Week High — Why Does Retail See A 'Solid Upside'?</a>

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Evogene on Tuesday announced that it had entered into a warrant inducement agreement for about  $3.4 million with an existing institutional investor. 

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.271
Prev Close	$0.3296
Open	$0.279
Dividend Yield	0.00%
50-Day Moving Average	$0.4274
Beta	0.85
Avg. Volume	140,416.77
PE Ratio	-0.30

52-Week High	$1.28
52-Week Low	$0.2503
Market Capitalization	$4.89M
EPS (Annual)	-$1.08
Price to Book	-1.11
Revenue Per Employee	$74,096.15

Feed

News

Sentiment

Earnings

Fundamentals

Info

EVGN Fundamentals